Form 4: Corcept Therapeutics Officer Lyon Exercises Options and Sells Shares
SEC Form 4
Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, exercised stock options and sold shares on May 9, 2024, according to a recent SEC filing.
Summary
- On May 9, 2024, Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, exercised stock options to acquire 7,227 shares of common stock at a price of $11.35 per share.
- Simultaneously, Lyon sold 7,227 shares of Corcept Therapeutics common stock at $26 per share.
- Following these transactions, Lyon directly owns 7,314 shares of Corcept Therapeutics common stock, which includes 1,411 shares underlying unvested restricted stock awards granted on June 1, 2023, 361 shares granted on September 1, 2023, 460 shares granted on December 1, 2023, and 507 shares granted on March 1, 2024.
- The sale was conducted under a pre-arranged 10b5-1 trading plan.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reflects a standard insider transaction. The officer exercised options and sold shares, which is a common practice.
Industry Context
This filing is a routine disclosure of insider transactions. It's common for executives to exercise stock options and sell a portion of the acquired shares for personal financial management.
Comparison to Industry Standards
- Insider trading activity is closely monitored across the pharmaceutical industry.
- Companies like AbbVie, Eli Lilly, and Pfizer also have similar insider trading policies and reporting requirements.
- The use of 10b5-1 plans is a standard practice to avoid accusations of trading on material non-public information.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders.
- Shareholders may view insider sales with caution, but the use of a 10b5-1 plan mitigates concerns about opportunistic trading.
Key Dates
| Date | Description |
|---|---|
| 06/01/2023 | Grant date of 1,411 unvested restricted stock awards. |
| 09/01/2023 | Grant date of 361 unvested restricted stock awards. |
| 12/01/2023 | Grant date of 460 unvested restricted stock awards. |
| 03/01/2024 | Grant date of 507 unvested restricted stock awards. |
| 05/09/2024 | Date of stock option exercise and share sale. |
| 02/08/2029 | Expiration date of stock options. |
| 05/13/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.